These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 2117289

  • 1. Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG.
    Soloway MS.
    Prog Clin Biol Res; 1990; 350():71-9. PubMed ID: 2117289
    [Abstract] [Full Text] [Related]

  • 2. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS, Jordan AM, Murphy WM.
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [Abstract] [Full Text] [Related]

  • 3. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 4. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [Abstract] [Full Text] [Related]

  • 5. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R.
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [Abstract] [Full Text] [Related]

  • 6. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM, van der Meijden AP, Franssen MP.
    Prog Clin Biol Res; 1989 Mar; 303():435-46. PubMed ID: 2506556
    [No Abstract] [Full Text] [Related]

  • 7. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL.
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [Abstract] [Full Text] [Related]

  • 8. When intravesical measures fail. Indications for cystectomy in superficial disease.
    Hudson MA.
    Urol Clin North Am; 1992 Aug; 19(3):601-9. PubMed ID: 1636242
    [Abstract] [Full Text] [Related]

  • 9. [BCG and radiotherapy: the compatibility of 2 conservative treatments for cancer of the urinary bladder].
    Sánchez-Martín FM, Palou Redorta J, Regalado Pareja R, Rubio Briones J, Villavicencio Mavric H, Vicente Rodríguez J.
    Arch Esp Urol; 1999 Sep; 52(7):749-58. PubMed ID: 10540765
    [Abstract] [Full Text] [Related]

  • 10. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J, Palou J, Millán Rodríguez F, Villavicencio Mavrich H, Rodríguez JV.
    Arch Esp Urol; 2002 Sep; 55(1):50-6. PubMed ID: 11957752
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T, Cancer Registration Committee of the Japanese Urological Association.
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [Abstract] [Full Text] [Related]

  • 17. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 18. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A, Bock PR.
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [Abstract] [Full Text] [Related]

  • 19. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M, Loertzer H, Horsch R, Keller H.
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [Abstract] [Full Text] [Related]

  • 20. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG?
    Badalato GM, Hruby G, Razmjoo M, McKiernan JM.
    Can J Urol; 2011 Oct; 18(5):5890-5. PubMed ID: 22018151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.